Rhythm Pharmaceuticals (RYTM) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

ProductLicense
010M20M30M40M50M60M70M80MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

Non-US
04M8M11M15M19M22M26M30MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development Expenses
08M15M22M30M38M45M52M60MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-70M-61M-52M-44M-35M-26M-17M-9M1Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-30-19-841526384960Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
012253850627588100Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-50-44-37-31-24-18-12-51Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
048111519222630Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
0625K1M2M2M3M4M4M5MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000111222Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000111222Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics